SAB Biotherapeutics
SABS
SABS
25 hedge funds and large institutions have $10.1M invested in SAB Biotherapeutics in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
less ownership
Funds ownership: →
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Holders
25
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$533K | |
| 2 | +$48.5K | |
| 3 | +$43.2K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.11K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.97K |
Top Sellers
| 1 | -$1.72M | |
| 2 | -$86.1K | |
| 3 | -$66.4K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$27.8K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.72K |